Tumour angiogenesis
PREDOCTORAL RESEARCHERS (R1)
- Maria Aparicio Garcia
- Roser Eulalia Pons Cursach
- Iratxe Zuazo Gaztelu
- Julia Sallaberry Pinto
- Iván Prieto Durán
SCIENTIFIC SUPPORT
- Maria Del Mar Martinez Lozano
- Alba Martinez Lopez
MANAGEMENT SUPPORT
- Gabriela Alejandra Jimenez Valerio
Cancer
Oncobell
Scientific production
5
PAPERS
1 PUBLICATIONS IN FIRST DECILE
*Average Journal IF
6 PUBLICATIONS IN FIRST QUARTILE
Selected publications
- Mireles M, Morales-Dalmau J, Johansson JD, Vidal-Rosas EE, Vilches C, Martínez-Lozano M, Sanz V, de Miguel I, Casanovas O, Quidant R, Durduran T. Non-invasive and quantitative in vivo monitoring of gold nanoparticle concentration and tissue hemodynamics by hybrid optical spectroscopies. NANOSCALE. 10.1039/c8nr08790c
- Morales-Dalmau J., Vilches C., Sanz V., De Miguel I., Rodríguez-Fajardo V., Berto P., Martínez-Lozano M., Casanovas O., Durduran T., Quidant R. Quantification of gold nanoparticle accumulation in tissue by two-photon luminescence microscopy. NANOSCALE. 10.1039/c9nr01198f
- Zuazo-Gaztelu I, Pàez-Ribes M, Carrasco P, Martín L, Soler A, Martínez-Lozano M, Pons R, Llena J, Palomero L, Graupera M, Casanovas O . Antitumor Effects of Anti-Semaphorin 4D Antibody Unravel a Novel Proinvasive Mechanism of Vascular-Targeting Agents. CANCER RESEARCH. 10.1158/0008-5472.CAN-18-3436
- Castet F, Garcia-Mulero S, Sanz-Pamplona R, Cuellar A, Casanovas O, Caminal JM, Piulats JM. Uveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope?. CANCERS. 10.3390/cancers11060834
- Capdevila, J; Teule, A; Barriuso, J; Castellano, D; Lopez, C; Manzano, JL; Alonso, V; Garcia-Carbonero, R; Dotor, E; Matos, I; Custodio, A; Casanovas, O; Salazar, R. Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study. ONCOLOGIST. 10.1634/theoncologist.2017-0622
Research highlights
PROJECTS
4 Ongoing projects
PUBLISHED WORKS
2 Theses
INNOVATION
1 Patent
Selected projects
- Mecanismos y Bloqueo de la Resistencia Intrínseca a los Anti-Angiogénicos en Cáncer Renal (30/12/2016 – 29/12/2019). PI: CASANOVAS CASANOVAS, ORIOL. Funder: MINISTERIO DE EDUCACION Y CIENCIA
- Desarrollo de un nuevo biomarcador y su kit para predecir la Resistencia a Antiangiogénicos en Cancer – AngioBIOMARK (1/1/2018 – 31/12/2019). PI: CASANOVAS CASANOVAS, ORIOL. Funder: FIS-Instituto de Salud Carlos III
- Angiotheragnostics (1/12/2019 – 31/5/2021). PI: CASANOVAS CASANOVAS, ORIOL. Funder: Fundació “La Caixa”
- Interacció Tumor Estroma i Resistència Terapèutica – ITERT (1/1/2018 – 31/12/2020). PI: CASANOVAS CASANOVAS, ORIOL . Funder: AGAUR-GENERAL.CATALUNYA
- Análisis de muestras del estudio Talent que gestiona Getne (12/4/2019- ). PI: CASANOVAS CASANOVAS, ORIOL. Ref: CI-008/19